BCL2L15抗体—艾普蒂

The BCL2L15 antibody targets the BCL2-like 15 protein, a member of the BCL-2 family known for regulating apoptosis. BCL2L15. also referred to as BCL2-related ovarian killer (BOK) in some contexts, shares structural homology with pro-apoptotic family members like BAX and BAK. It contains conserved BCL-2 homology (BH) domains critical for mediating interactions with other apoptotic regulators. Unlike classical anti-apoptotic BCL-2 proteins, BCL2L15 exhibits context-dependent roles, with studies suggesting involvement in both pro-survival and pro-death pathways, particularly in response to endoplasmic reticulum (ER) stress or DNA damage. Its expression is tissue-specific, enriched in reproductive and gastrointestinal tissues. Dysregulation of BCL2L15 has been linked to cancer progression, neurodegenerative disorders, and reproductive pathologies. Antibodies against BCL2L15 are essential tools for studying its expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. These reagents help clarify its ambiguous functional mechanisms and potential therapeutic relevance. Commercial BCL2L15 antibodies are typically developed in rabbits or mice, validated for specificity across human and model organism samples. Ongoing research aims to resolve controversies regarding its primary role in apoptosis and its utility as a biomarker or drug target.